Biofluidica, Inc., a privately held biotechnology company, today announced they will be introducing their new biomarker isolation platform, LiquidScan™, at the annual AACR Conference on April 10-13 in New Orleans. The novel platform isolates and enhances biomarker population directly from a blood draw replacing the need for surgical biopsies and making available potential tests for tissues not available for biopsy.
BioFluidica to Introduce Next-Generation Biomarker Isolation Platform
